JP2024538015A - 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン - Google Patents

治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン Download PDF

Info

Publication number
JP2024538015A
JP2024538015A JP2024520807A JP2024520807A JP2024538015A JP 2024538015 A JP2024538015 A JP 2024538015A JP 2024520807 A JP2024520807 A JP 2024520807A JP 2024520807 A JP2024520807 A JP 2024520807A JP 2024538015 A JP2024538015 A JP 2024538015A
Authority
JP
Japan
Prior art keywords
fdck
administered
treatment
depression
antidepressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538015A5 (https=
Inventor
ゴラン，エゼキエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clearmind Medicine Inc
Original Assignee
Clearmind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearmind Medicine Inc filed Critical Clearmind Medicine Inc
Publication of JP2024538015A publication Critical patent/JP2024538015A/ja
Publication of JP2024538015A5 publication Critical patent/JP2024538015A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024520807A 2021-10-18 2022-10-18 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン Pending JP2024538015A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256728P 2021-10-18 2021-10-18
US63/256,728 2021-10-18
PCT/IB2022/060011 WO2023067505A1 (en) 2021-10-18 2022-10-18 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression

Publications (2)

Publication Number Publication Date
JP2024538015A true JP2024538015A (ja) 2024-10-18
JP2024538015A5 JP2024538015A5 (https=) 2025-10-27

Family

ID=84178934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520807A Pending JP2024538015A (ja) 2021-10-18 2022-10-18 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン

Country Status (8)

Country Link
US (1) US20250032429A1 (https=)
EP (1) EP4419092A1 (https=)
JP (1) JP2024538015A (https=)
KR (1) KR20240093579A (https=)
CN (1) CN118401239A (https=)
AU (1) AU2022374097A1 (https=)
CA (1) CA3233107A1 (https=)
WO (1) WO2023067505A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094757A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CN119241381A (zh) * 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途

Also Published As

Publication number Publication date
US20250032429A1 (en) 2025-01-30
EP4419092A1 (en) 2024-08-28
CA3233107A1 (en) 2023-04-27
CN118401239A (zh) 2024-07-26
WO2023067505A1 (en) 2023-04-27
AU2022374097A1 (en) 2024-03-14
KR20240093579A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
DeBattista et al. Antidepressant agents
Haas et al. Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
CN114712356A (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
KR20140136982A (ko) 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
US20030232805A1 (en) Prevention and treatment of functional somatic disorders, including stress-related disorders
JP5491475B2 (ja) ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置
Kaye et al. Perioperative implications of common and newer psychotropic medications used in clinical practice
US20050096395A1 (en) Methods of treating attention deficit/hyperactivity disorder (adhd)
US10795976B2 (en) Program randomization for cyber-attack resilient control in programmable logic controllers
US10576045B2 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
Reinhold et al. Major depressive disorder
JP2024538015A (ja) 治療抵抗性うつ病を含むうつ病の治療のための２－フルオロデスクロロケタミン
CA3186900A1 (en) Compositions and methods for treating psychiatric disorders or symptoms thereof
Stock et al. Pharmacological treatment of paediatric
JP2025510790A (ja) 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途
US20230084299A1 (en) Improved antidepressant therapy
Balfour et al. Venlafaxine extended-release: A review of its clinical potential in the management of generalised anxiety disorder
Zohar et al. Pharmacological Treatment of Obsessive‐Compulsive Disorder: A Review
KR20140069120A (ko) S1p 수용체 조절제를 포함하는 조합물
HK40048114B (zh) 用於治疗抑郁症的右美沙芬和安非他酮的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260212